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Electrochemical aptasensors may be used to detect protein biomarkers related to tumor activity. Os-
teopontin (OPN), a protein present in several body ﬂuids, has been suggested as a potential biomarker
since its overexpression seems to be associated with breast cancer progression and metastasis. In this
work, a simple and label-free voltammetric aptasensor for the detection of OPN, using an RNA aptamer
previously reported to have afﬁnity for human OPN as the molecular recognition element, and the ferro/
ferricyanide solution as a redox probe, was developed. The RNA aptamer was synthetized and im-
mobilized in a working microelectrode gold surface (diameter of 0.8 mm) of a screen-printed strip with a
silver pseudo-reference electrode and a gold counter electrode. The electrochemical behavior of the
electrode surface after each preparation step of the aptasensor was studied using cyclic voltammetry and
square wave voltammetry. The resulting voltammetric aptasensor was used to detect OPN in standard
solutions. Cyclic voltammetry results showed that the aptasensor has reasonable detection and quanti-
ﬁcation limits (3.770.6 nM and 1172 nM, respectively). Indeed, the detection limit falls within the
osteopontin levels reported in the literature for patients with metastatic breast cancer. Moreover, the
aptasensor is able to selectively detect the target protein in the presence of other interfering proteins,
except for thrombin. Considering the overall results, a possible application of the aptasensor for cancer
prognosis may be foreseen in a near future.
& 2015 Elsevier B.V. All rights reserved.1. Introduction
Breast cancer is a major cause of mortality among women
worldwide. According to the International Agency of Research on
Cancer (IARC) and World Health Organization (WHO), in 2012, 1.67
million women were diagnosed with breast cancer, the second
most common cancer in women and the ﬁfth leading cause of
death (522,000 deaths) (Ferlay et al., 2013). Breast cancer is a
complex disease with a very heterogeneous clinical nature, for
which it is crucial to identify new biomarkers associated with
tumor growth, angiogenesis and metastasis (Thorat et al., 2013).
Osteopontin (OPN) is a multifunctional phosphorylated glycopro-
tein, expressed as a 41–75 kDa protein due to varied post-trans-
lational modiﬁcations (Anborgh et al., 2011; Tuck et al., 2007; Wai
and Kuo, 2008). OPN can be found in all body ﬂuids and isde Gualtar, 4710-057 Braga,
eirinho).considered as a potential serum tumor marker (Macrì et al., 2009;
Rodrigues et al., 2007; Tuck et al., 2007; Weber et al., 2011, 2010), a
possible therapeutic target for blocking tumor growth and sub-
sequent metastasis, as well as a cancer regulator (Mi et al., 2009a;
Rodrigues et al., 2009). Recent studies demonstrated that circu-
lating levels of OPN contribute to the tumor formation and ag-
gressiveness, progression and metastasis (Ahmed and Kundu,
2010; Bache et al., 2010; Bramwell et al., 2014; Mirza et al., 2008;
Rodrigues et al., 2007). Increased OPN protein levels in serum or
tumor have been associated with several clinical parameters, such
as tumor stage, tumor grade, tumor subtype, tumor size and the
time of relapse (Bache et al., 2010). In breast cancer, a high OPN
expression, measured both in plasma and tumor tissue, has been
associated with a decreased survival (Bramwell et al., 2006), as
well as poor prognosis and disease progression (Rudland et al.,
2002; Weber et al., 2010). In 2014, Bramwell et al. (2014) were able
to measure, using enzyme-linked immunosorbent assay (ELISA)
the OPN levels in plasma samples of patients with metastatic
breast cancer. The results showed that plasma OPN concentrations
in patients with metastatic breast cancer were on average 46 ng/
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Nowadays, traditional methodologies, such as mammography
and ELISA, are used for early detection of breast cancer and de-
tection of OPN in plasma, respectively. However, these techniques
present some limitations, thus it is of utmost relevance to develop
new non-invasive methods for the detection of tumor markers
detection, as for example the detection of OPN in body ﬂuids.
These non-invasive methods would allow following the patients'
treatment or facilitate the detection of breast cancer in an early
stage of the disease, thus enabling an increased success of cancer
treatments. Electrochemical aptasensors may be a suitable alter-
native to the above mentioned diagnosis methods. Technically,
aptasensors can be fabricated to respond to any target molecule
for which an aptamer can be generated. Several electrochemical
aptasensors have been reported for the speciﬁc detection of bio-
marker proteins in body ﬂuids, such as thrombin (Xiao et al.,
2005a, 2005b), C-reactive protein (Centi et al., 2009) and platelet-
derived growth factor (PDGF) (Lai et al., 2007). Electrochemical
detection has attracted considerable attention in the development
of aptasensors since it exhibits high sensitivity, simple in-
strumentation, low production cost, fast response, and portability
(Arshak et al., 2009; Radi, 2011; Saberian et al., 2011; Song et al.,
2008; Velasco-Garcia and Missailidis, 2009; Velusamy et al., 2010;
Xu et al., 2009). On the other hand, aptamers are short single-
stranded DNA or RNA oligonucleotides with high afﬁnity and
speciﬁcity for a speciﬁc protein, which can be obtained using a
selection process, namely the systematic evolution of ligands by
exponential enrichment (SELEX). The dissociations constants of
aptamer–target complexes typically range from the low micro-
molar to high picomolar levels (Jing et al., 2011). The potential use
of aptamers in clinical applications implies understanding the
aptamer–protein interactions. In the literature, several methods
for dissociations constants determination have been described
including dialysis, ultraﬁltration, electrophoretic mobility shift gel,
afﬁnity capillary electrophoresis, ﬂuorescence intensity and ani-
sotropy, UV–vis absorption and circular dichroism, surface plas-
mon resonance and isothermal titration calorimetry (Jing et al.,
2011; Tran et al., 2010). Aptamers are easy to synthesize and
chemically modify, possessing high sensitivity and selectivity to-
wards the target, good stability in complex environments and re-
sistance to denaturation and degradation. Therefore, aptamers are
ideal biological recognition elements for the development of bio-
sensors, especially if compared with antibody-based strategies
(Hianik and Wang, 2009; Radi, 2011; Song et al., 2012; Strehlitz
et al., 2008). Recently, Mi et al. (2009b) isolated an RNA aptamer
against human OPN (dissociation constant (Kd) of 18 nM) using
SELEX, which could be further explored in the development of an
electrochemical biosensor to detect OPN. Indeed, more recently,
Cao et al. (2014), proposed an electrochemical aptasensor method
for the detection of human OPN using the square wave voltam-
metry (SWV) technique with a pyrolytic graphite disk electrode
(3.0 mm diameter), functionalized with gold nanoparticles in
synthetic host macromolecule substrate, and the same RNA–ap-
tamer (Mi et al., 2009b). This electrochemical method allowed
detecting human OPN with a detection limit of 10.7 ng/mL (Cao
et al., 2014). However, the application of nanomaterials increase
the cost of the biosensor and, in complex samples, its reproduci-
bility and quantiﬁcation may be affected (Yu et al., 2012). On the
other hand, Chen et al. (2014), developed an electrochemical im-
munosensor for human OPN detection through the impedance
spectroscopy technique, which had a detection limit of 0.17 nM.
Though, as mentioned above, aptamers present some advantages
over immunological compounds, and the number of applications
involving their use greatly increased in the recent years.
In this work, a simple electrochemical aptasensor for the de-
tection of human OPN was developed based in a preliminary studyof our research group (Meirinho et al., 2014). For that purpose, the
RNA aptamer previously described by Mi et al. (2009b) was stu-
died in its aptamer–rhOPN binding afﬁnity using ﬂuorescence
assays and as an aptasensor through its immobilization in a screen
printed gold electrode (SPGE) by streptavidin–biotin interaction.
Cyclic voltammetry (CV), with a [Fe(CN)6]3–/4– redox probe, was
used to evaluate the biosensor performance towards human OPN
detection, as well as the inﬂuence of other interfering proteins. As
a complementary technique, square wave voltammetry (SWV) was
also applied to follow the steps of the aptasensor construction,
enabling a comparison between the observed electrochemical
behaviors after each step.2. Experimental
2.1. Material and reagents
Recombinant human osteopontin (rhOPN, 65 kDa) and re-
combinant bovine osteopontin (rbOPN, 60 kDa) were purchased
from R&D Systems. Thrombin from human plasma (THR, 37.4 kDa),
Bovine serum albumin (BSA, 66 kDa), lysozyme from chicken egg
white (LYS, 14.3 kDa) and streptavidin were obtained from Sigma-
Aldrich. All proteins were acquired lyophilized and manipulated
according to the manufacturers’ speciﬁcations. Diethypyr-
ocarbonate (DEPC), 3,3-dithiodipropionic acid (DPA), N-(3-di-
methylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC),
N-hydroxysuccinimide (NHS), ethanolamine (ETA) and sulfuric
acid (purity of 99.999%) were obtained from Sigma-Aldrich. Po-
tassium hexacyanoferrate (III) (K3Fe(CN)6) and potassium hex-
acyanoferrate (II) (K4Fe(CN)6) were obtained from Acros Organics
and potassium dihydrogen phosphate (KH2PO4) from Merck. So-
dium chloride (NaCl), potassium chloride (KCl) and sodium hy-
drogen phosphate (Na2HPO4) were acquired from Panreac. All
chemicals were of analytical grade and used as received. Deionized
water (18.2 MΩ) puriﬁed by a milli-QTM system (Millipore) was
used throughout the experiment for aqueous solutions
preparation.
Phosphate buffer saline (PBS) solution (137 mM NaCl, 2.7 mM
KCl, 8.1 mM Na2HPO4 and 1.47 mM KH2PO4) with an adjusted pH
of 7.4 was used. The ferro/ferricyanide redox probe (5 mM
K3Fe(CN)6 and K4Fe(CN)6 (1:1), and 10 mMKCl in 100 mL of PBS),
with an adjusted pH of 7.4, was daily prepared.
Stock solutions of 200 mM EDC, 100 mM NHS, as well as the
stock solution 1 mg/ml of septravidin in PBS (pH 7.4) were stored
at 20 °C before use. Stock solutions of 200 nM DPA and 100 mM
of ethanolamine (ETA) were stored at 4 °C. Stock solutions of each
protein were prepared according to the manufacturer speciﬁca-
tions and stored at 20 °C. The protein working solutions were
obtained by dilution with PBS buffer (pH 7.4) and stored at 4 °C
until use.
2.1.1. RNA aptamer
The RNA aptamer herein used was reported by Mi et al.
(2009a). The sequence of the biotinylated RNA aptamer (5′-Biotin-
CGGCCACAGAAUGAAAAACCUCAUCGAUGUUGCAUAGUUG-3′) was
synthesized by Integrated DNA Technologies (Belgium).
Stock solutions (100 mM) of the synthetic oligonucleotides were
prepared with ultra-pure water containing 1% DEPC (v/v) to avoid
the RNase interference. The working RNA aptamer solution was
prepared by dilution using fresh PBS. Before the RNA aptamer
immobilization on the gold working electrode, the biotinylated
RNA aptamer prepared in PBS buffer (pH 7.4) was subjected to a
temperature treatment (95 °C during 5 min, 4 °C for 5 min and
10 min at room temperature) in order to obtain an adequate
structure ﬂexibility of the aptamer for the interaction with
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2.2. Apparatus
Electrochemical analyzes were performed at room temperature
using a Potentiostat-Galvanostat device (PG580, Uniscan Instru-
ments). The screen-printed gold electrodes (SPGEs) (DropSens, S.
L., Spain) has a gold working electrode with a diameter of 0.8 mm,
as well as a silver pseudo-reference electrode and a gold counter
electrode. The pH was measured using a pH meter (iHANNA in-
struments pH 211). The ﬂuorescence measurements were per-
formed in 96-dark-well plates using an ELISA reader (Synergy HT,
BIO-TEK, IZASA) equipped with thermostat holding a temperature
control accuracy of 0.1 °C and conﬁgured with 492 nm excitation
and 518 nm emission ﬁlters. The Gen5TM data analysis software
was used for collecting microplate data and conducting the ana-
lysis after settle a range of excitation and emission wavelengths.
2.3. Fluorescent aptamer–protein binding afﬁnity assays
Fluorescence assays were performed to evaluate the binding
afﬁnity of the RNA aptamer towards rhOPN. For that purpose, a
ﬂuorophore 6-carboxyﬂuorescein (FAM) was attached to the 5′-
end of the RNA aptamer sequence (i.e., 5′-FAM-CGGCCACAGAAU-
GAAAAACCUCAUCGAUGUUGCAUAGUUG-3′), which was supplied
by Alfagene (Portugal). Before each ﬂuorescence assay, the FAM-
RNA aptamer was heated at 95 °C during 5 min, then cooled at 4 °C
for 5 min and ﬁnally 10 min at room temperature to facilitate the
folding of the aptamer.
First, the ﬂuorescence of the FAM-RNA aptamer was studied.
FAM-RNA aptamer solutions with concentrations varying from
2.5 to 100 nM were prepared and the related ﬂuorescence in-
tensity of the free aptamer (non-bound to any protein) was mea-
sured. The different solutions of FAM-RNA aptamer were in-
cubated for 30 min and 4 h at room temperature. After this, the
solutions were excited at 492 nm and ﬂuorescence was measured
at 518 nm. Based on these assays, calibration curves relating the
ﬂuorescence intensity and FAM-RNA aptamer concentrations were
established for both incubation times (30 min and 4 h), enabling
the evaluation of the ﬂuorescence contribution of the free aptamer
and, if necessary, the estimation of the free aptamer concentration
for the binding aptamer–protein studies.
Regarding the aptamer–protein complex formation, a 20 nM
FAM-RNA aptamer solution was prepared in PBS buffer at pH 7.6.
For each ﬂuorescence assay, 60 mL of a 20 nM solution of RNA
aptamer modiﬁed with FAM-RNA–aptamer, were incubated with
the same volume of different concentrations of rhOPN (0, 3, 10,
100, 300, 370 nM) prepared in the same buffer (Potty et al., 2009;
Tran et al., 2010), in 96-dark-well plates. The mixtures were in-
cubated at room temperature for two different periods, i.e. 30 min
and 4 h. The mixture was excited at 492 nm and ﬂuorescence was
measured at 518 nm.
Since THR is a protein present in the human blood and could
act as an interferent during the electrochemical analysis of blood
samples, these same experiments were also conducted for THR.
Indeed, rhOPN contains a THR cleavage domain, thus the RNA
aptamer could hold a site that may also recognize THR.
2.4. Aptamer–protein binding afﬁnity parameter
Fluorescence data were further used to determine the dis-
sociation constant (Kd), which is the reciprocal of the binding
pseudo-equilibrium constant of the aptamer–protein complex
formation. A one-to-one binding aptamer–protein stoichiometry
was assumed (i.e. identical and equivalent binding sites for protein
and aptamer), thus it was supposed that one mole of protein couldonly bind to one mole of aptamer.
Brieﬂy, the aptamer–protein complex (P-APT) formation may be
represented by the equation proposed by Jing et al. (2011)
P APT P APT (1)+ ↔ −
being P and APT the protein and aptamer, respectively.
In this case, the dissociation constant could be calculated by
K
P APT
P APT
[ ][ ]
[ ] (2)
d = −
where [P] and [APT] are the concentrations of free protein and free
aptamer, i.e. non-bound, respectively.
Including the fraction of bound aptamer ( f APT), as the ratio
between the concentrations of bound aptamer and the total ap-
tamer (for assays with constant initial aptamer concentration and
increasing protein concentrations, i.e. when RNA aptamer is ti-
trated with a broad concentration range of protein), the following
equation can be established:
f
APT
APT
P APT
P APT APT
[ ]
[ ]
[ ]
[ ] [ ] (3)
APT
bound
initial
= = −
− +
Considering one-to-one equilibrium, APT[ ] [ P APT]bound = − and
APT APT APT[ ] [ ] [ ]initial bound= + can be assumed.
Afterwards, replacing P APT[ ]− in Eq. (3) with the result of the
Eq. (2) the following relation can be derived:
f
P
K P
[ ]
[ ] (4)APT d
=
+
and after rearranging
f
P K
f
K[ ]
1
(5)
APT
d
APT
d
= −
Eq. (5) is often known as the Scatchard equation and a straight
line with a slope equal to
K
1
d
− will be obtained by plotting f
P[ ]
APT
versus f APT. This procedure allows a straightforward calculation of
the Kd value and to infer about the binding afﬁnity between the
aptamer and the protein. Alternatively, Kd can be calculated using
non-linear optimization algorithms using Eq. (4). In both cases, it
is necessary to estimate f APT experimentally and the concentration
of free protein ( P[ ]) after each protein addition, assuming that the
pseudo-equilibrium described by Eq. (1) is attained.
Some points must be considered, namely if the initial aptamer
concentration is signiﬁcantly smaller than Kd (i.e., APT K[ ] initial d), the
free protein concentration P[ ] at equilibrium does not change sig-
niﬁcantly from the total protein concentration added, P[ ]t upon
binding (i.e. P P[ ] [ ]t≈ ) and so Eq. (8) could be simpliﬁed to the one
proposed by Jing et al. (2011)
f
P K
f
K[ ]
1
(6)
APT
t d
APT
d
= −(i) It is recommended to use data across the binding fraction
range (i.e. fAPT values) of 0.2–0.8 (Jing et al., 2011).(ii) The values of f APT must be calculated using Eq. (3) based on the
concentration of bound aptamer ([APTbound]) estimated using
the experimental ﬂuorescence data.Hence, to estimate APT[ ]bound the following procedure could be
implemented. If both the aptamer non-bound and the aptamer–
protein complex formed (FAPT and FP APT− , respectively) exhibit
ﬂuorescence, then the total ﬂuorescence measured (Ft) would re-
sult from:
F F F (7)t APT P APT= + −
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(intercept a and slope b) of the calibration curve obtained by
measuring the ﬂuorescence of increasing aptamer concentration
solutions without the presence of the protein,
F a b APT[ ] (8)APT = +
and FP APT− may be estimated assuming a proportionality coefﬁcient
between ﬂuorescence intensity and the complex concentration,
P APT[ ]− , like
F c P APT[ ] (9)P APT = −−
being the coefﬁcient c estimated based on the constant maximum
ﬂuorescence intensity observed in the titration curve (increasing
protein concentrations added to a ﬁxed initial aptamer con-
centration), a situation where all the initial APT is bound to P (no
free APT is available in the solution), thus all measured ﬂuores-
cence would be due to the P APT− complex, which concentration,
for a one-to-one binding stoichiometry, could be assumed as:
P APT APT[ ] [ ] (10)initial− =
and so,
c
F
APT[ ] (11)
t maximum
initial
,=
Replacing Eqs. (8)–(11) into the Eq. (7), and by using the rela-
tions between the concentrations of protein and aptamer, bound
or free, it is possible to obtain an explicit equation for APT[ ]bound:
F a b APT
F
APT
P APT[ ]
[ ]
[ ]
(12.1)
t
t,maximum
initial
= + + −
F a b APT APT
F
APT
APT([ ] [ ] )
[ ]
[ ]
(12.2)
t
t
initial bound
,maximum
initial
bound= + − +
APT
F a b APT
b
[ ]
[ ]
(12.3)
bound
t initial
F
APT[ ]
t maximum
initial
,
= − −
−
Finally, Eq. (3) could be modiﬁed to enable the direct calcula-
tion of f APT from experimental ﬂuorescence data:
f
APT[ ] (13)APT
F a b APT
b
[ ]
initial
t
F t
APT
initial
,maximum
[ ]initial=
− −
−
When the RNA–aptamer concentration approaches or is greater
than Kd ( APT K[ ] dinitial ≥ ), this parameter should not be calculated
using Eq. (6) since P[ ] cannot be considered equal to P[ ]t and so, in
Eq. (6) the free protein concentration should be replaced by:
P P P P P APT[ ] [ ] [ ] [ ] [ ] (14)t tbound= − = − −
Similarly,
APT APT APT APT P APT[ ] [ ] [ ] [ ] [ ] (15)initial bound initial= − = − −
Therefore, by making these replacements in Eq. (2) the fol-
lowing equation for the complex concentration may be derived, as
described by Jing et al. (2011)
( )
P APT
P APT K
P APT K P APT
[ ]
[ ] [ ]
[ ] [ ] 4[ ] [ ]
2
(16)
t d
t d t
initial
initial
2
initial− =
+ +
− + + −
Finally, by replacing these equations in Eq. (4) an expression isobtained for the case where the initial aptamer concentration is
not smaller than the dissociation constant:
( )
( )
f
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K P
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APT
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P APT K P APT K P APT
d t
P APT K P APT K P APT
[ ] [ ] [ ] [ ] 4[ ] [ ]
2
[ ] [ ] [ ] [ ] 4[ ] [ ]
2
t initial d t initial d t initial
t initial d t initial d t initial
2
2
=
−
+ −
+ + − + + −
+ + − + + −
Combining Eqs. (13) and (17) it is then possible to calculate Kd
value by applying a non-linear optimization algorithm.
In this study, Kd values were estimated using the Levenberg–
Marquardt nonlinear least-squares minimization method. This
optimization procedure uses the gradient descent and Gauss–
Newton minimization algorithms, ensuring that a solution is found
even if the starting values of the unknown terms are not close to
those obtained in the ﬁnal adjustment. The ﬁrst algorithm is ap-
plied when the sum of squared deviations is large and, the second,
when the optimal value is approached (Bloomﬁeld, 2014). The
Levenberg–Marquardt method was applied using the package
minpack.lm Timur (2013) of the R software.
2.5. RNA aptamer immobilization
The electrochemical-based aptamer biosensor was obtained
using a biotinylated RNA aptamer immobilized on a streptavidin-
modiﬁed gold electrode surface (Fig. 2A).The substances, con-
centrations, temperatures and times used in the RNA aptamer
immobilization steps were established based on data reported in
the literature (Kim et al., 2010; Xiao et al., 2005a).
First, the working gold electrode surface was cleaned successively
with three solutions (0.5 M H2SO4, 0.01 M KCl/0.1 M H2SO4 and
0.05 M H2SO4) under electric potential in the range of 0.3–1.5 V,
and at scan rate of 100 mV/s. An etching step, with [Fe(CN)6]3 /4
solution, was carried out to ensure the homogeneity of the working
gold surface. Afterwards, a self-assembled monolayer (SAM) was
formed through an incubation step, using a 200 mM solution of DPA
(30 min at room temperature). The working electrode was then
washed with ultra-pure water and treated with 100 mM solution of
EDC and 1 mM solution of NHS (1:1 v/v, 60 min at room tempera-
ture) to activate the carboxyl groups, which facilitates the binding
with the amino group of streptavidin during overnight incubation
with streptavidin solution (4 °C). The working electrode was then
exposed to ethanolamine (100 mM, pH 8.5, during 20 min at room
temperature) to block any remaining activated carboxyl groups. Fi-
nally, the biotinylated RNA aptamer was attached to the modiﬁed
gold surface using the streptavidin–biotin interaction (40 min at
room temperature) and the surface was rinsed thoroughly with PBS
buffer (pH 7.4) to remove the free aptamers. For the detection of
rhOPN, a standard solution of protein in PBS (pH 7.4) was dropped
(E5 μL) on the working electrode and incubated for 60 min at room
temperature.After washing the electrode with PBS, to further remove
non-binding rhOPN, 60 mL of [Fe(CN)6]3/4solution (redox probe)
was dropped on the electrodes chip until all three electrodes were
immersed. After this procedure CV assay was carried out to assess
the level of RNA aptamer binding to the protein tested. All changes
obtained in each preparation step of the aptasensor were followed by
CV since it is a simple, rapid and sensitivity technique, which gives
overall information regarding the reversibility of the oxidation and
reduction mechanisms that occur at the electrode surface (Farghaly
and Hameed, 2014). This electrochemical technique worked as a
quality control tool and it allowed establishing typical redox probe
cyclic voltammograms to monitor the effectiveness of the working
electrode surface modiﬁcation. If in any of the preparation steps, the
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carded. SWV was also applied, for comparative purposes, to verify if
the electrochemical behavior recorded after each preparation step
during the aptasensor construction was similar for both techniques.
2.6. Electrochemical measurements
CV is widely used in electrochemical analysis to characterize
electroactive compounds and electrode surfaces. This method in-
volves linear forward and backward scanning within a ﬁxed po-
tential range, recorded at the working electrode, being the plot of
the observed current versus the applied potential, the cyclic vol-
tammogram. Anodic and cathodic peak current intensities and the
respective potentials, at which these peaks are observed, provide
valuable information regarding system reversibility and can be
used to elucidate the oxidation/reduction mechanism at the elec-
trode surface. Therefore, all electrodes used were evaluated and
further characterized using CV and the electrochemical measure-
ments were performed in the presence of [Fe(CN)6]3/4 at room
temperature. The CV measurements were performed under a po-
tential range of 0.5 –0.6 V and at a scan rate of 50 mV/s.
The current decrease (relative current change (ΔI %)) was cal-
culated considering the current values of the cyclic voltammogram
anodic peak recorded after aptamer immobilization and protein
solution incubation by using the Eq. (18):
I I I I% ( )/ 100 (18)0 1 0Δ = − ×
where ΔI is relative current change (%); I0 and I1 represents the
current before and after the sample incubation, respectively.
The detection limit (LOD) and quantiﬁcation limit (LOQ) were
calculated based on the linear relationship obtained between ΔI %
values of anodic peak current and different rhOPN concentrations.
The detection limit and the quantiﬁcation limits are calculated by
the equations LOD¼3(SD/b) and LOQ¼10(SD/b), respectively,
where SD is the standard deviation of the intercept and b is the
average slope of the regression line (Ermer and Miller, 2005).
SWV was also used since it is a fast and sensitive pulse method
for which a symmetric square wave is superimposed on a staircase
potential. The current is measured twice during each square wave
cycle, at the end of the forward and reverse pulses, being the
current difference plotted against the applied base potential. The
SWV response is peak-shaped and the peak potential matches
with the half-wave potential for a simple reversible ion transfer
mechanism (Farghaly and Hameed, 2014). Under the CV optimized
conditions, the SWV signal changes were observed for a potentialFig. 1. (A) Calibration curves of FAM-RNA aptamer for two incubation periods (30 min a
increasing rhOPN concentrations in PBS buffer pH 7.6 at 30 min and 4 h of incubation trange of 0.5 V to 0.6 V, at a frequency of 100 Hz, an amplitude of
50 mV and scan increment of 5 mV.3. Results and discussion
3.1. Evaluation of the aptamer–rhOPN binding afﬁnity
The aptamer–rhOPN binding evaluation was performed using
ﬂuorescence assays. First, ﬂuorescence intensities were measured
for increasing concentrations of FAM-RNA aptamer, enabling the
establishment of two calibration curves for two incubation periods
(30 min and 4 h), as shown in Fig. 1A. Secondly, the aptamer–
rhOPN complex formation was followed by measuring the ﬂuor-
escence intensity after the addition of different rhOPN con-
centrations to a solution with 20 nM of FAM-RNA aptamer. The
Fig. 1B shows the titration curve obtained for the two above-
mentioned incubation periods. This ﬁgure shows that total ﬂuor-
escence increases with increasing rhOPN concentration, thus
suggesting that the aptamer–protein complex exhibits ﬂuores-
cence. Hence, the ﬂuorescence intensity values measured result
from the individual contribution of the non-bond aptamer and
aptamer–rhOPN complex formed. These ﬂuorescence data (Fig. 1A
and B) were used together with the equations described in Section
2.4 to verify the aptamer–rhOPN complex formation by means of
Kd estimation. Since for the RNA aptamer used in this work, a Kd
value of 18.070.2 nM was already reported by Mi et al. (2009b),
based in electrophoretic mobility shift assays, the Kd values for the
FAM-RNA aptamer were calculated using the mathematical pro-
cedure for [APT]ZKd (Eqs. (13) and (17)). Assuming only one ap-
tamer–rhOPN high afﬁnity-binding site, Kd values of 1.6 nM and
8.5 nM were estimated for 30 min and 4 h, respectively. These
results pointed out that with an incubation of 30 min the binding
site seems to have a higher afﬁnity for rhOPN (lower Kd value),
showing that this time-period is sufﬁcient to ensure the aptamer–
rhOPN binding.
3.2. Electrochemical evaluation of the electrode surface
The voltammetry assays were conducted to verify the electro-
chemical behavior of the electrode surface after each preparation
step of the aptasensor. CV is a valuable and convenient tool to
monitor the barrier of the modiﬁed electrode. This tool allows
measuring electron transfer between the solution species and the
electrode that must occur by tunneling either through the barriernd 4 h), and (B) Titration curve of 6-carboxyﬂuorescein-labeled RNA aptamer with
ime. The concentration of RNA aptamer probe was ﬁxed in 20 nM.
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is a more sensitive technique and was use to conﬁrm the CV re-
sults in each step of the aptamer preparation. For these electro-
chemical studies, a 5 mM solution of [Fe(CN)6]3/4 was used asFig. 2. (A) Schematic illustration of an RNA aptamer immobilized onto a working gold
(C) Square wave voltammograms of 5 mM [Fe(CN)6]3 /4 probe in PBS buffer solutio
electrode, cleaning, DPA, EDC/NHS, streptavidin, ETA, RNA aptamer and aptamer–rhOPNthe redox probe.
Fig. 2 shows the various immobilization steps towards RNA
aptamer onto a working gold electrode (Fig. 2A) and the sensor
voltammograms obtained in each preparation steps using cyclicelectrode through streptavidin–biotin interaction. (B) Cyclic voltammogramsand
n of pH 7.4 at scan rate of 50 mV/s for all aptasensor preparation steps: bare Au
protein.
Table 1
Electrochemical parameters obtained after each electrode surface preparation
steps.
Steps ▵Ep (mV) Ipa (mA) Ipc (mA)
Bare Au electrode 100710 6.970.6 6.970.4
Cleaning 17578 6.070.2 5.970.3
DPA 200710 5.6870.04 5.3870.04
EDC-NHS 8775 7.470.4 7.670.4
Strepatvidin 11878 5.870.5 6.470.6
ETA 137715 5.970.5 6.670.4
RNA aptamer 143710 5.670.2 6.470.2
rhOPN 245717 4.1470.08 4.870.2
CV-Cyclic voltammogram; ΔEp-potential variation between cathodic and anodic
peaks; Ipc-cathodic peak current value; Ipa-anodic peak current value. Mean va-
lues7standard deviation of three or more replicas are presented.
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Using the cyclic voltammograms data, electrochemical parameters
were calculated namely, the potential variation between cathodic
and anodic peaks (ΔEp), the cathodic peak current value (Ipc) and
anodic peak current value (Ipa), which are given in Table 1. The
results shown are mean values obtained from assays using dif-
ferent SPGEs and prepared in different days.
The ﬁrst cyclic voltammogram in Fig. 2B1, recorded with the
[Fe(CN)6]3/4 redox solution, shows the quasi-reversible elec-
trochemical behavior of the gold electrode surface without any
treatment, with peaks separation of 100 mV (ΔEp) and with si-
milar cathodic and anodic peaks current intensities (Table 1). The
current response decreased slightly after the cleaning steps with
different H2SO4 solutions, which may be due to achieving a
homogeneous surface. After the DPA self-assembled monolayer
formation on the electrode surface, an expected decrease of the
peaks current intensities was observed, as well as an increase of
ΔEp, which may be due to the electron transfer blocking. Subse-
quently, the electrode surface was activated with EDC-NHS (acti-
vation of the carboxyl groups), which resulted in an increase of the
peaks current intensities (Fig. 2B2) and a decrease in the ΔEp
giving a voltammogram close to a reversible behavior. The acti-
vated carboxylic groups on the electrode surface facilitate the
binding of the streptavidin amine’s groups.
The streptavidin layer in the electrode surface increased the
ΔEp value and decreased the current peaks intensities, when
compared to the previous step. After exposing the working surface
electrode to ETA, aiming to block any remaining activated carboxyl
groups, the cyclic voltammogram obtained showed an increase in
the ΔEp and in the current peaks as compared with the previous
one, which may be due to some non-speciﬁc blocking of the re-
maining free carboxylic groups. After the aptamer immobilization
on electrode surface, the typical cyclic voltammogram (Fig. 2B3)
showed similar ΔEp and lower current peaks comparing to the
previous steps. Because of the negative charges of the aptamer
backbone phosphate group and [Fe(CN)6]3/4 redox probe, the
electrostatic repulsive interaction is expected to block the electron
transfer (Bang et al., 2005).This experiment clearly demonstrated
the effective immobilization of the aptamer onto the working
electrode surface. The differences between the cyclic voltammo-
grams obtained after the aptasensor preparation and after its in-
cubation with a standard rhOPN solution (1540 nM) are sig-
niﬁcant. Indeed, for the rhOPN analysis, the cyclic voltammogram
showed the highest potential variation between peaks and the
lowest current peaks comparing with all the seven previous steps.
The decrease of peak current intensities is an evidence of the ap-
tamer–rhOPN complex formation, by means of the speciﬁc re-
cognition increased hindered electron transfer. This signal-off
sensing mechanism (negative readout signal) in the current after
aptamer-target interaction could be attributed to a change of theaptamer conformation.
SWV was also used for monitoring each biosensor construction
step (Fig. 2C). From the visual comparison of the cyclic voltam-
mograms and SWV voltammograms plots (Fig. 2B and C, respec-
tively) it can be concluded that the order of the peak current in-
tensities for all the biosensor’s preparation steps is equivalent,
showing that both techniques allow monitoring the electro-
chemical changes occurred during the electrode surface prepara-
tion. However, the differences observed in the plots for SWV (of
Fig. 2C) are more evident, which was expected considering its
higher sensitivity compared to CV. The maximum current in-
tensities of all SWV voltammograms were recorded at a potential
range from 0.06 to 0.075 V. As expected, Fig. 2C1 shows that at the
bare Au electrode, the redox probe exhibited maximum peak in-
tensity at the potential 0.075 V and a decrease of 50% in current
intensity after the cleaning step with different H2SO4 solutions
(current intensity maximum at potential 0.060 V) and a decrease
of 64% after the DPA immobilization (current intensity maximum
at potential 0.065 V). After the electrode surface activation with
EDC-NHS (Fig. 2C2), the current intensity attained was slightly
lower comparing to the result for the bare Au electrode (signal
decrease of 7%). The Fig. 2C2 also showed the current intensity
decrease due to the binding of the streptavidin amine’s groups in
the electrode surface (corresponding to 40% decrease compared to
the bare Au electrode signal) and a shift to a higher potential
(0.075 V). As result of the application of the ETA, to block any re-
maining activated carboxyl groups, the SWV showed a reduced
current intensity peak compared with the previous step, but at the
same potential value. In the Fig. 2C3, it is clear the difference be-
tween the surface response of the bare gold electrode after the
aptamer immobilization on electrode surface (considering all the
described previous steps) and after rhOPN incubation (with a
standard solution of 1540 nM). The current intensity of the vol-
tammograms recorded after the aptamer immobilization de-
creased 56% compared with the signal observed for the bare gold
surface, with a potential shift to lower value (0.07 V) and, for after
rhOPN analysis incubation an even higher decrease was observed
(78% compared to that of the bare gold surface), showing a po-
tential shift to an even lower potential value (0.06 V). These last
variations, as in CV results, demonstrate the aptamer–rhOPN
complex formation and the existence of a current signal-off sen-
sing mechanism (negative readout signal).
The CV technique was chosen to evaluate the quality control of
the aptasensor preparation and to evaluate its analytical perfor-
mance in the detection of proteins since it allowed obtaining in-
formation about the sensor surface’s oxidative and reducing pro-
cess. Overall, these two electrochemical techniques enable mon-
itoring each immobilization step used in construction of the RNA
aptamer into the working gold electrode and that aptamer–protein
interaction results in a decrease of the current response.
3.3. Optimization of experimental conditions
The experimental conditions were optimized in order to obtain
an aptasensor with a high sensitivity. Several RNA aptamer con-
centrations, times and temperatures were evaluated to improve
the aptamer immobilization on the working gold modiﬁed surface.
Also, the incubation time of rhOPN with the aptasensor, was
optimized.
For the RNA aptamer concentration studies, several SPGEs ap-
tasensors were prepared with different concentrations of RNA
aptamer (2.5 nM, 4 nM, 0.1 mM, 0.5 mM and 1 mM) for 40 min at
room temperature, as described in Section 2.5. Afterwards, each
aptasensor was incubated with a rhOPN solution (1540 nM) for
one hour at room temperature. Fig. 3A shows the current relative
change (ΔI %) obtained from the redox solution probe CV after the
Fig. 3. (A) Optimization of the biotin–RNA aptamer concentration: several con-
centrations of aptamer have been tested (2.5 nM, 4 nM, 0.1 mM, 0.5 mM and 1 mM).
The aptamer concentration has been chosen comparing the relative current signals
measured in presence and in absence of rhOPN. Mean values7standard deviation
of three or more replicas are presented; (B) Effect of the incubation time of the
rhOPN solution.
Fig. 4. (A) CV response for rhOPN detection at different concentrations: (1) RNA
aptamer immobilized, (2) 100.1 nM, (3) 200.2 nM, (4) 800.8 nM and (5) 2402.4 nM.
(B) Electrochemical aptasensor sensitivity analysis of rhOPN using an aptamer-
immobilized gold working electrode. Error bars indicate the relative standard de-
viation of three independent experiments. The insert shows the linear relationship
between the ΔI (%) and the rhOPN concentrations.
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values were obtained for the aptasensor prepared with an RNA
aptamer concentration of 4 nM. For concentrations higher than
4 nM there was a decrease in the ΔI % values. Therefore, the im-
mobilization with an RNA aptamer concentration of 4 nM was
chosen for the following studies since it promoteda greater dif-
ference between the signals after immobilization of aptamer and
after protein inoculation.The incubation time of the RNA aptamer
in the gold working electrode was also evaluated, namely for
40 min and 2 h (data not shown). The ΔI % values obtained for the
two time incubation were also very similar, being the incubation
time set equal to 40 min.
Regarding the temperature selection for the immobilization of
the aptamer, two temperatures were evaluated, namely 4 °C and
room temperature. The assays were conducted using a 4 nM RNA
aptamer solution that was incubated during 40 min in the SPGEs
modiﬁed surfaces. The ΔI % values obtained from the cyclic vol-
tammograms after incubation of rhOPN (1540 nM) were similar
for both temperatures. Thus, all experiments were further carried
out at room temperature.
Another important parameter to increase the sensitivity and
selectivity of the aptasensor is the incubation time of the target
protein. This factor can affect the formation of the aptamer-target
complex and therefore must be evaluated. A series of modiﬁed
electrodes prepared with 4 nM biotin–RNA aptamer were in-
cubated with 1540 nM of rhOPN solution for 15, 30, 60 and
120 min at room temperature. As shown in Fig. 3B, theΔI % values
increased gradually with the increase of the incubation time, and
it was found to remain almost constant after 60 min of protein
incubation. Thus, an incubation time of 60 min was chosen as the
optimal time for the aptamer–protein complex formation and itwas used in the following experiments.
3.4. Electrochemical detection of rhOPN
The performance of the aptasensor was evaluated under the
experimental conditions selected, taking into account its response
(ΔI % values) to standard solutions containing different con-
centrations of rhOPN. Each rhOPN determination was carried out
using different SPGEs.The cyclic voltammograms of the
[Fe(CN)6]3/4 solution (redox probe) showed an electrochemical
response that could be related to the aptamer surface modiﬁcation
and, in this case, to the amount of aptamer–rhOPN interactions,
which is dependent on the rhOPN concentrations. The CV assays
showed a decrease in the current response (Ipa and Ipc) as a
consequence of the increase of the rhOPN concentration (Fig. 4A).
Fig. 4B illustrates the ΔI % values as a function of the rhOPN
concentration. The results suggest that the increasing values of
ΔI % are proportional to the increase of the rhOPN concentration,
in the rhOPN concentration range between 25 nM and 2402 nM,
reaching signal saturation near 800 nM. A linear correlation could
be established for a dynamic concentration range from 25 nM and
200 nM (ΔI %¼ 0.0591(70.0007) [rhOPN, nM]þ1.81(70.08),
Fig. 4B).
The linear correlation coefﬁcient was 0.999 and the calculated
detection and quantiﬁcation limits were 3.770.6 nM and
1172 nM (240 ng/mL and 715 ng/mL, assuming a molecular
weight of 65 kDa), respectively. This detection limit was quite
improved compared to the previous preliminary work of the re-
search group (520 ng/mL) (Meirinho et al., 2014), but higher than
Fig. 5. Bar chart of CV response (ΔI %) to non-speciﬁc proteins (200 nM): BSA —
bovine serum albumin, LYS — lysozyme, rbOPN — bovine osteopontin and THR —
thrombin and for speciﬁc-protein rhOPN – human osteopontin. Error bars indicate
the relative standard deviation of three independent experiments.
S.G. Meirinho et al. / Biosensors and Bioelectronics 71 (2015) 332–341340those previously reported for the detection of human OPN
(7.48 ng/ mL (Chen et al., 2014) and 10.7 ng/mL (Cao et al., 2014)),
obtained using different measurement techniques, type of elec-
trodes and biosensor preparation methodology. Considering the
reported range of plasma OPN concentrations in patients with
metastatic breast cancer (up to 290 ng/mL) (Bramwell et al., 2014)
the proposed aptasensor still could be applied in OPN detection.
Also, in the present study, a smaller gold working electrode was
used, compared to previous works (Cao et al., 2014; Chen et al.,
2014), contributing to the miniaturization of the sensor, as well as
the reduction of the amount of reagents and samples’ volumes
required for the detection.
On the other hand, the future application of other voltammetry
techniques, such as square wave voltammetry (SWV) and differ-
ential pulse voltammetry (DPV) could increase the sensitivity of
the proposed analysis. Indeed, the SWV compared to CV is a
technique that presents broader dynamic range and lower limit of
detection. Also, SWV enables a faster analysis with less con-
sumption of electroactive compounds that DPV and consequently
reducing blocking problems of the electrode surface (Dogan-Topal
et al., 2010). Finally, the use of aptamers as biological recognition
elements instead of antibody or antigen (immunological detec-
tion) makes the proposed method less expensive and therefore, an
interesting commercial alternative. Also, the use of aptamers
presents some advantages such as ease and reduced cost of pro-
duction, as well as the possibility of introducing some chemical
modiﬁcations to enhance stability, afﬁnity and speciﬁcity towards
the target. Moreover, aptamers can be immobilized on a large
number of transducers surfaces (Balamurugan et al., 2008; Hianik
and Wang, 2009; Radi, 2011; Song et al., 2012, 2008; Strehlitz
et al., 2008). On other hand, the possible use of new materials or
nanoparticles could contribute to reduce the detection limits, since
the electrode surface area could be greatly increased and conse-
quently more aptamers could be immobilized, thus contributing to
an increase of the sensitivity and speciﬁcity.
3.5. Speciﬁcity of aptasensor
A highly selective response to the target protein over other
non-speciﬁc proteins is crucial when developing biosensors. Se-
lectivity is a key factor to evaluate the aptasensor performance.
The selectivity test was carried out by measuring and comparing
the response of the RNA aptamers to rhOPN and to some other
non-speciﬁc proteins (THR, BSA, LYS and rbOPN), all at a con-
centration of 200 nM. The THR was analyzed as a possible inter-
ferent because it is a secreted serine protease found in the blood
(Beausoleil et al., 2011). The other proteins, though not present in
human body ﬂuids were also analyzed. The rbOPN was analyzed
because it exhibits a cDNA sequence with high degree of homology
with that of rhOPN (Wai and Kuo, 2004). The BSA and LYS were
used to analyze if the effect of the proteins molecular weight could
affect the detection. For each individual protein determination,
different SPGE were used. Fig. 5 illustrates the ΔI % obtained for
rhOPN and also for the non-speciﬁc proteins tested. The results
showed that the RNA aptamer had a good sensitivity to rhOPN
when compared with the proteins BSA, LYS and rbOPN. However,
their ΔI % values cannot be neglected and a more pronounced
response was observed in the presence of THR. Aptamers are de-
scribed as small single-stranded RNA or DNAwith high afﬁnity and
speciﬁcity for a given target molecule. However, some aptamers
can also bind to other molecules presenting similar structures
without losing their speciﬁcity (Lakhin et al., 2013). The possible
aptamer cross-reactivity may explain the results obtained for THR.
The rhOPN and THR structures are not similar. Nonetheless, the
rhOPN contains several conserved domains including THR clea-
vage domain RSK site, leading to the breakdown of the protein intotwo fragments (Beausoleil et al., 2011; Sivakumar and Niranjali
Devaraj, 2014). Thus, during the process of RNA aptamer selection,
the cleavage of OPN might have occurred, and therefore the RNA
aptamer could hold a site that is able to recognize THR. The results
obtained suggest that the RNA aptamer used in this work may
have two recognition sites, one for rhOPN and another for THR.
To assess the possible RNA aptamer binding afﬁnity towards
THR, ﬂuorescence assays were also performed using the same
procedure described in Section 2.3 (experimental conditions) and
Section 2.4 (mathematical procedure). For FAM-RNA aptamer-THR
complex formation, aKd value of 1.3 nM was obtained for 4 h of
incubation. This result suggests that the RNA aptamer may have a
binding site for THR, with a higher afﬁnity than that observed for
rhOPN (Kd,THRoKd,rhOPN).3.6. Reproducibility and stability of the aptasensor
To evaluate the reproducibility of the aptasensor, four different
SPGEs were prepared in the same day, under the same conditions
and tested using a solution with a concentration of 1540 nM of
rhOPN. Also, seven other SPGEs were prepared in different days
and tested with 200 nM rhOPN. The current response obtained
from the aptasensors prepared in the same and different days
showed a relative standard deviation (RSD %) of 4.2% and 5.7%,
respectively, thus suggesting that the aptasensor preparation
method was reproducible and precise. The overall experimental
results indicate that the aptasensor used in this work had a good
reproducibility (RSD % less than 6%).
The aptasensor stability was also evaluated since this is another
important parameter for the practical application of a sensor. To
evaluate this parameter, the RNA aptamer half-life was studied.
Our results were compared with the ones reported by Mi et al.
(2009b) and Talbot et al. (2011), that reported half-lives of 8 h and
more than 24 h for in vitro assays and human serum, respectively
(Mi et al., 2009b; Talbot et al., 2011). The aptasensor stability was
evaluated by comparing the ΔI % of three SPGEs, prepared under
the same experimental conditions, and stored during 2, 4, 6, 8 h
and 10 days. When compared with the initial ΔI % value, the re-
sponse after 8 h and 10 days, was still 95% and 88%, respectively,
showing a satisfactory stability of the aptasensor response along
time. This result may explain the difﬁculty in regenerating the
aptamer, even when using different regeneration solutions (e.g.
2 M of NaCl or 7 M of urea).
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This work represents a proof-of-principle that the proposed
electrochemical aptasensor is a simple and sensitive tool with
satisfactory performance, reproducibility and stability for the de-
tection of rhOPN. However, the developed aptasensor is not fully
speciﬁc for the target protein when other interfering species are
present. Therefore, further studies are required, namely in the
selection of new and more speciﬁc aptamers against rhOPN, in
order to improve its detection performance and selectivity, as well
as the implementation of other voltammetric techniques such as
square wave voltammetry (SWV) and differential pulse voltam-
metry (DPV), which are also used in the development of
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